- Report
- March 2022
Japan, United States, ... Japan, United States, Europe
From €1320EUR$1,450USD£1,121GBP
From €1684EUR$1,850USD£1,430GBP
- Company Profile
- April 2025
From €1684EUR$1,850USD£1,430GBP
- Company Profile
- April 2025
From €1684EUR$1,850USD£1,430GBP
- Company Profile
- April 2025
From €1684EUR$1,850USD£1,430GBP
- Company Profile
- April 2025
From €1684EUR$1,850USD£1,430GBP
- Company Profile
- April 2025
From €1320EUR$1,450USD£1,121GBP
- Company Profile
- April 2025
From €1320EUR$1,450USD£1,121GBP
The Prostate Specific Antigen (PSA) Test is a diagnostic tool used to detect the presence of prostate cancer in men. It measures the amount of PSA, a protein produced by the prostate gland, in the blood. Elevated levels of PSA may indicate the presence of prostate cancer, although other conditions such as benign prostatic hyperplasia can also cause elevated PSA levels. The PSA Test is typically used in conjunction with other tests such as digital rectal examination and biopsy to confirm a diagnosis of prostate cancer.
The PSA Test market is a subset of the larger Diagnostics market, which includes a wide range of tests used to diagnose and monitor diseases. The Diagnostics market is highly competitive, with a variety of companies offering a range of products and services.
Some companies in the Prostate Specific Antigen Test market include Abbott Laboratories, Beckman Coulter, Siemens Healthineers, Roche Diagnostics, and Quest Diagnostics. Show Less Read more